

1 **Title:** Estimating the risk of COVID-19 death during the course of the outbreak in Korea, February-
2 March, 2020

3 **Running title:** Case fatality of COVID-19 in Korea

4
5 **Authors:** Eunha Shim, PhD¹, Kenji Mizumoto, PhD^{2,3,4}, Wongyeong Choi, B.Sc.¹, Gerardo Chowell,
6 PhD²

7
8 **Affiliations:**

- 9 1. Department of Mathematics, Soongsil University, Seoul, Republic of Korea 06978. E-mail
10 address: alicia@ssu.ac.kr; chok10004@soongsil.ac.kr
11 2. Department of Population Health Sciences, School of Public Health, Georgia State University,
12 Atlanta, GA, USA. 30303 E-mail address: gchowell@gsu.edu
13 3. Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University,
14 Kyoto, Japan 615-8530. Email: mizumoto.kenji.5@kyoto-u.ac.jp
15 4. Hakubi Center for Advanced Research, Kyoto University, Yoshidahonmachi, Sakyo-ku, Kyoto,
16 Japan 615-8530

17
18 **Corresponding author:** Eunha Shim (alicia@ssu.ac.kr), Department of Mathematics, Soongsil
19 University, Korea. Tel: +82 (10) 2383-5309. Fax: +82 (2) 824-4383.

20
21 **Word count**

22 Abstract: 200

23 Main (MAX): 2,584

24

25 **Abstract**

26 **Background:** In Korea, a total of 8,799 confirmed cases of COVID-19 including 102 deaths have been
27 recorded as of Mar 21, 2020. The time-delay adjusted case fatality risk of COVID-19 in Korea is yet to be
28 estimated.

29
30 **Methods:** We obtained the daily series of confirmed cases and deaths in Korea reported prior to March 21,
31 2020. Using statistical methods, we estimated the time-delay adjusted risk for death from COVID-19 in the
32 city of Daegu, Gyeongsangbuk-do, other regions in Korea, as well as for the entire country.

33
34 **Results:** Our model-based crude CFR fitted the observed data well throughout the course of the epidemic
35 except for the very early stage in Gyeongsangbuk-do, partially due to the reporting delay. Our estimates of
36 the risk for death in Gyeongsangbuk-do reached 2.4% (95% CrI: 1.6-3.4%), 1.3% (95% CrI: 1.0-1.6%) in
37 Daegu and 0.7% (95% CrI: 0.3-1.4%) in other regions, whereas the national estimate of the risk for death
38 was estimated at 1.4% (95% CrI: 1.2-1.7%) in Korea.

39
40 **Conclusions:** The relatively low CFRs are associated with the early implementation of public health
41 interventions including widespread testing, social distancing, and delayed school openings in Korea.
42 Geographic differences in CFR are likely influenced by clusters of nosocomial transmission.

43
44 **Keywords:** Coronavirus, COVID-19, Korea, fatality, deaths, case fatality risk

45
46
47

48 **Introduction**

49 Since the first reports of cases from Wuhan in the Hubei Province of China in December 2019, more than
50 82,000 cases of 2019 novel coronavirus disease (COVID-19) including 3,293 deaths have been reported in
51 China [1]. Based on the estimates by a joint World Health Organization (WHO)-China fact-finding mission,
52 the epidemic in China peaked between late January and early February 2020 [2]. However, the virus has
53 been seeded in numerous countries and is now generating sustained outbreaks in many areas of the world
54 with the rate of new cases outpacing the rate of China. As of March 21, 2020, the global cumulative number
55 of reported infections and deaths were 266,073 and 11,183, respectively [1]. Outside China, new cases
56 initially occurred mainly among travelers from China and their contacts, but local transmission is now
57 driving major outbreaks in numerous countries including U.S., Italy, Spain, Germany, and Iran [1].

58 The spread of 2019 novel coronavirus disease (COVID-19) in South Korea started on Jan 19, 2020,
59 when the first confirmed case of Chinese nationality entered the country from Wuhan, China [3]. Since
60 then, SARS-CoV-2 has continued to spread in Korea in the form of a series of clusters of variable size and
61 geographic location in addition to imported cases [4]. As of March 21, 2020, the cumulative number of
62 COVID-19 reported cases and deaths in Korea are at 8,799 and 102, respectively [5].

63 In order to accurately estimate the epidemiological and economic burden with an emerging
64 infectious disease, assessing the associated risk for death from the disease as well as its transmission
65 potential are critical. Although the transmission modes of COVID-19 are not entirely understood, person-
66 to-person spread via respiratory droplets appears to be the main mode of transmission. The transmissibility
67 of COVID-19 was found to be relatively high, with the mean basic reproduction number in the range 1.4-
68 1.6 in Korea ([4]) and 2-7.1 for China [6-13]. In the absence of vaccines against COVID-19 or antiviral
69 drugs for its treatment, epidemic control relies on the implementation of symptom monitoring and non-
70 pharmaceutical interventions such as social distancing and movement restrictions. It is worth noting that in
71 Korea, movement restriction orders represent legal public health measures, including quarantine (isolation),
72 home isolation, or controlled travel [14].

73 Assessing the severity of infection of COVID-19 is useful to anticipate the risk of death during the
74 course of the epidemic as well as hypothesize factors that may be driving the risk of death in different
75 geographic areas. The crude case fatality risk (CFR) can be measured by estimating the proportion of the
76 cumulative number of deaths out of the cumulative number of cases at a point in time, which underestimates
77 severity due to the real-time nature of the growth in the number of fatal cases. This is due to the delays from
78 case notification to death. On the other hand, the denominator is calculated based on confirmed cases only,
79 and thus may overestimate the actual CFR based on all infected individuals, resulting in ascertainment bias.
80 Nevertheless, Korea has instituted broad scale testing efforts at the core of the control interventions [15].
81 Therefore, the present study aims to estimate the risk of death among confirmed cases while addressing
82 ascertainment bias and a right-censored likelihood for modeling the count of deceased cases by using
83 established methods [16]. In order to estimate the current severity of the COVID-19 epidemic in Korea, we
84 report the estimates of the time-delay adjusted CFR for COVID-19 for the city of Daegu, Gyeongsangbuk-
85 do, Other regions (i.e., outside Daegu and Gyeongsangbuk-do) and for Korea, with quantified uncertainty.

86

87 **Method**

88 **Data sources**

89 We obtained the daily series of confirmed cases and deaths in Korea from daily reports published by the
90 Korea Centers for Disease Control and Prevention (KCDC) [5]. These data were categorized by geographic
91 area: Daegu, Gyeongsangbuk-do, Other regions, or Korea, considering that over 70% of the deaths are
92 occurring in Daegu. The virus that causes COVID-19, SARS-CoV-2 RNA, is detected by reverse-
93 transcription polymerase chain reaction (RT-PCR), and according to the Center for Laboratory Control of
94 Infectious Diseases in KCDC, the upper limit of Ct value for positive RT-PCR of SARS-CoV-2 is 35, and
95 the negative criterion is Ct value 37 or higher [17]. Our analysis relies on epidemiological data reported
96 prior to March 21, 2020.

97

98 **Case fatality ratio**

99 Crude CFR is defined as the number of cumulative deaths divided by the number of cumulative cases at a
 100 specific point in time. For the estimation of CFR in real time, we employ the delay from hospitalization to
 101 death, h_s , which is assumed to be given by $h_s = H(s) - H(s-1)$ for $s > 0$ where $H(s)$ is a cumulative density
 102 function of the delay from hospitalization to death and follows a gamma distribution with mean 10.1 days
 103 and SD 5.4 days, according to a recent study that estimated the CFR in China [18]. We let π_{a,t_i} be the time-
 104 delay adjusted case fatality ratio on reported day t_i in area a . The likelihood function of the estimate π_{a,t_i} is
 105 calculated as

$$106 \quad L(\pi_{a,t_i}; c_{a,t}) = \prod_{t_i} \binom{\sum_{t=1}^{t_i} c_{a,t}}{D_{a,t_i}} \left(\pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{D_{a,t_i}} \left(1 \right. \\
 107 \quad \left. - \pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{\sum_{t=1}^{t_i} c_{a,t} - D_{a,t_i}}$$

108 where $c_{a,t}$ represents the number of new cases with reported day t in area a , and D_{a,t_i} is the cumulative
 109 number of deaths until reported day t_i in area a [18-20]. Among the cumulative cases with reported day t in
 110 area a , D_{a,t_i} have died and the remainder have survived the infection. The contribution of those who have
 111 died with biased death risk is shown in the middle parenthetical term and the contribution of survivors is
 112 presented in the right parenthetical term. We assume that D_{a,t_i} is the result of the binomial sampling process
 113 with probability π_{a,t_i} .

114 We estimated model parameters using a Monte Carlo Markov Chain (MCMC) method in a
 115 Bayesian framework. Posterior distributions of the model parameters were estimated by sampling from the
 116 three Markov chains. For each chain, we drew 100,000 samples from the posterior distribution after a burn-
 117 in of 20,000 iterations. Convergence of MCMC chains were evaluated using the potential scale reduction
 118 statistic [21, 22]. Estimates and 95% credibility intervals for these estimates are based on the posterior
 119 probability distribution of each parameter and based on the samples drawn from the posterior distributions.
 120 All statistical analyses were conducted in R version 3.6.1 (R Foundation for Statistical Computing, Vienna,
 121 Austria) using the ‘rstan’ package.

122

123 **Results**

124 As of March 21, 2020, a total of 8,799 cases and 102 deaths of COVID-19 have been reported in
125 Korea. Of the 8,799 cases reported in Korea, 6,344 cases (72.1 %) are from Daegu, 1,243 cases (14.1 %)
126 are from Gyeongsangbuk-do. Of the 102 deaths in Korea, 73 deaths (71.6%) are from Daegu, 24 deaths
127 (23.5 %) are from Gyeongsangbuk-do and only five deaths (4.9 %) are from other areas in Korea.

128 Figure 1 illustrates the cumulative cases in (A) Korea, (B) Daegu, (C) Gyeongsangbuk-do, and (D)
129 Other regions, and the cumulative deaths in (E) Korea, (F) Daegu, (G) Gyeongsangbuk-do and (H) Other
130 regions, respectively. The curve of the cumulative number of deaths grows after that of the cumulative
131 number of cases, and the increase in the number of deaths in Daegu is occurring more rapidly and the
132 associated mortality burden appears to be much higher compared to the rest of Korea.

133 Figure 2 displays the observed and model-based posterior estimates of crude CFR in (A) Korea,
134 (B) Daegu, (C) Gyeongsangbuk-do, and (D) Other regions, and model-based posterior estimates of the
135 time-delay adjusted CFR in (E) Korea, (F) Daegu, (G) Gyeongsangbuk-do and (H) Other regions, in
136 February – March, 2020. Our model-based crude CFR fitted the observed data well throughout the course
137 of the epidemic except for the very early stage in Gyeongsangbuk-do, probably affected by the reporting
138 delay of confirmed cases. During the course of the outbreak, our model-based posterior estimates of time-
139 delay adjusted CFR take much higher values than the observed crude CFR. Our estimates of the time-delay
140 adjusted CFR appear to be decreasing almost consistently in all of the three areas, whereas in
141 Gyeongsangbuk-do, estimates were low at the early stage and then increased and peaked in the midst of the
142 study period, and are now following a decreasing trend similar to the other two areas, reaching estimates
143 around 2.5%.

144 The latest estimates (March 21, 2020) of the time-delay adjusted CFR are at 1.3% (95% CrI: 1.0-
145 1.6%) in Daegu, 2.4% (95% CrI: 1.6-3.4%) in Gyeongsangbuk-do, 0.7% (95% CrI: 0.3-1.4%) in Other
146 regions and 1.4% (95% CrI: 1.2-1.7%) in Korea, while the observed crude CFR is 1.2% (95% CI: 0.9-1.4%)

147 in Daegu, 2.0% (95% CI: 1.2-2.9%) in Gyeongsangbuk-do, 0.4% (95% CrI: 0.1-1.0%) in Other regions and
148 1.2 % (95% CI: 0.9-1.4%) in Korea, respectively. (Figure 3, Table 1)

149

150 **Discussion**

151 In this paper we have derived estimates of the CFR for the ongoing COVID-19 epidemic in Korea,
152 a country that has relies on intensive social distancing and mass testing of suspected COVID-19 cases to
153 mitigate incidence levels of the disease and deliver early medical care to the most vulnerable, potentially
154 lowering the risk of death. Specifically, we have estimated time-delay adjusted CFR in three different
155 geographic areas in Korea and found that the most severely affected areas were Gyeongsangbuk-do while
156 the rest of Korea exhibits milder severity impact. Specifically, the delay-adjusted CFR in Gyeongsangbuk-
157 do, largely driven by hospital-based transmission, was relatively high, being estimated at 2.4% (95% CrI:
158 1.6-3.4%), which is about 2-fold higher than our estimate for Daegu and for all regions in Korea. These
159 findings suggest that the situation in Gyeongsangbuk-do is more severe compared with the other affected
160 areas in Korea.

161 One can note a considerable increase in fatality risks with older age by multiple folds, with the
162 oldest age group exhibiting the highest case fatality. It was also reported that the risk of symptomatic
163 infection also increases with age, although this may be partially affected by preferential ascertainment of
164 older and thus more severe cases [23]. In fact, a substantial fraction of the case-patients were elderly or had
165 underlying conditions [24]. The youngest case-patient was a 35-year old Mongolian male who already had
166 complications from chronic hepatic failure with cirrhosis and esophageal variceal bleeding [24]. The second
167 youngest case-patient was a 40-year old male with hypertension who was diagnosed with COVID-19 after
168 death [24]. Besides these two cases, all deaths associated with COVID-19 in Korea occurred among
169 individuals of age over 50. Such age-dependency of COVID-19 fatality indicates the importance of
170 monitoring infected individuals with old age and/or underlying medical conditions.

171 Our estimate time-adjusted CFR associated with COVID-19 in all regions in Korea is 1.4% (95%
172 CI: 1.2-1.7%). While this remains lower than the reported CFR for other coronaviruses such as SARS [25]

173 and MERS [26], it is relatively higher than the estimates from the 2009 H1N1 influenza pandemic [27, 28].
174 In addition, our estimates on CFR are relatively lower than the CFR obtained from affected areas in China
175 (ranging from 1.41% - 5.25%), based on the cases and deaths observed to date [18, 29]. In general, the CFR
176 of the same disease might vary greatly in different countries or even different regions of the same country,
177 partially due to differences in health control policies, availability of healthcare, medical standards, and
178 detection efficiency. In Korea, an extensive COVID-19 testing regime has been instituted, and authorities
179 launched a massive contact tracing as case numbers grew. As a result, the country has tested more people
180 per capita than any country in the world, with a total of 327,509 people as of March 21, 2020 [5]. Such
181 extensive testing might have effectively identified COVID-19 cases even with mild symptoms, thus
182 lowering the CFR.

183 The reported CFR of COVID-19 tends to vary over the course of epidemic curve. It is noteworthy
184 that the upward trend of CFR during the early phase generally indicates increasing ascertainment bias.
185 During a growing epidemic the final clinical outcomes of most reported cases are unknown, and thus
186 underestimating the true CFR early in the epidemic. Such effect was observed in our results (Fig. 2) as well
187 as in prior studies of past epidemics of respiratory pathogens including SARS and H1N1 influenza [30, 31].
188 Similarly, the observed time lag between onset of symptoms and outcomes tends to bias the estimated CFR
189 downwards during the early growth phase of an epidemic.

190 When the transmission of COVID-19 was widely recognized by clusters of confirmed cases such
191 as hospital-based transmission, surveillance is typically biased towards detecting clinically severe cases,
192 therefore resulting in higher CFR estimates. Specifically, hospital-based transmission has occurred during
193 the outbreak of COVID-19 in Korea, including clusters based in Cheongdo Daenam Hospital (resulting in
194 120 infections), Hansarang Convalescent Hospital (75 infections) and Gyeongsan Seo Convalescent
195 Hospital (30 infections) in Gyeongsangbuk-do, which explains our higher CFR estimate at 2.4% (95% CrI:
196 1.6-3.4%) for Gyeongsangbuk-do. Similarly, nosocomial clusters also occurred in Bundang Je-saeng
197 Hospital (38 infections) in Gyeonggi province, KimSin Recuperation Hospital (26 infections) in Daegu,
198 and Eunpyeong St Mary's Hospital (14 infections) in Seoul [5]. Such hospital-based transmission resulted

199 in secondary infections affecting healthcare workers, inpatients and their visitors, which tend to elevate
200 CFR estimates as has been previously documented for outbreaks of Middle East respiratory syndrome
201 (MERS) and severe acute respiratory syndrome in the past [32, 33]. In addition, a large number of COVID-
202 19 cases are related to church clusters in Korea, including a total of 5,037 COVID-19 cases in a cluster
203 linked to the Shincheonji Church, accounting for about 57% of all confirmed cases [5].

204 Asymptomatic patients complicate the estimation of CFR for COVID-19. In fact, the transmission
205 of SARS-CoV-2 from asymptomatic individuals (or individuals within the incubation period) has also been
206 described [34-36]. For instance, in a COVID-19 outbreak on a cruise ship, about half of the 619 confirmed
207 COVID-19 cases were asymptomatic at the time of diagnosis [37]. Moreover, some of patients with
208 asymptomatic infection showed objective clinical abnormalities. In a previous study of 24 patients with
209 asymptomatic infection and their chest computed tomography (CT), 50 percent of those had typical ground-
210 glass opacities or patchy shadowing, and another 20 percent had atypical imaging abnormalities [38]. In
211 addition, it is likely that asymptomatic or very mild cases were not reported, and thus were not included in
212 our analysis, possibly overestimating our CFR. Future research and more accurate incidence data including
213 age-stratified serologic studies would improve our estimates.

214 During the course of the epidemic, estimates of the time-adjusted CFR for Daegu, Gyeongsangbuk-
215 do, other regions (outside Daegu and Gyeongsangbuk-do) as well as all regions in Korea showed a declining
216 trend. A downward trend in time-adjusted CFR after its peak suggests the extent of improvement in
217 epidemiologic surveillance. In addition, a downward trend in CFR is partially due to a substantial number
218 of mild or asymptomatic cases, which might prolong the end of the outbreak [18]. We note that a similar
219 trend was previously reported for the COVID-19 outbreak in China, and for the 2015 MERS outbreak in
220 South Korea.

221 In conclusion, our estimates of the risk for death from COVID-19 in Korea as of March 21, 2020,
222 were as high as 2.4% in Gyeongsangbuk-do and as low as 0.7% in the less severely affected areas in Korea,
223 and this difference in CFR is likely influenced by nosocomial transmission of the disease. In the absence
224 of pharmaceutical interventions (i.e., vaccination and antiviral drugs), the control of COVID-19 is highly

225 dependent on public health interventions including social distancing measures, isolation of the infected,
226 delayed school openings, and extensive testing of potential contacts of confirmed cases. The estimates of
227 CFR associated with COVID-19 is thus critical to help inform the assessments of health impacts and to
228 determine both the intensity and appropriateness of mitigation strategies as the epidemic unfolds.

229 **Table legends:**

230 **Table 1.** Summary results of time-delay adjusted case fatality ratio of COVID-19 in the 3 areas in Korea,
231 2020 (As of March 21st, 2020)

232 **Table 2.** Distribution of the cases by sex and age groups, as of Mar 20, 2020 [5]

233 **Figure legends:**

234 **Figure 1: Temporal distribution of cases and deaths by area due to COVID-19, Korea, February –**
235 **March** **2020.**

236 Cumulative cases in (A) Korea, (B) Daegu, (C) Gyeongsangbuk-do, and (D) Other regions, and cumulative
237 deaths in (E) Korea, (F) Daegu, (G) Gyeongsangbuk-do and (H) Other regions, over time. Day 1
238 corresponds to February 1st in 2020. As the dates of illness onset were not available, we used dates of
239 reporting.

240 **Figure 2: Temporal variation of risk of death caused by COVID-19, Korea, February – March**
241 **2020.**

242 Observed and posterior estimated of crude case fatality ratio in (A) Korea, (B) Daegu, (C) Gyeongsangbuk-
243 do, and (D) Other regions, and time-delay adjusted case fatality ratio in (E) Korea, (F) Daegu, (G)
244 Gyeongsangbuk-do and (H) Other regions. Day 1 corresponds to February 1st in 2020. Black dots show
245 crude case fatality ratio, and light and dark indicates 95% and 50% credible intervals for posterior estimates,
246 respectively.

247

248 **Figure 3. Latest estimates of time-delay adjusted risk of death caused by COVID-19 by area, March**
249 **2020, Korea.**

250 Distribution of time-delay adjusted case fatality risks derived from the latest estimates (March 21st 2020)
251 are presented. Korea (national) (top) followed by Daegu, Gyeongsanbuk-do, and other regions (bottom).

252

253

254 **Acknowledgements**

255

256 **Conflicts of interests:** We declare no competing interests.

257


258 **Funding:** This work was supported by the National Research Foundation of Korea (NRF) grant funded by
259 the Korea government (MSIT) [No. 2018R1C1B6001723] to ES and WC. KM acknowledges support from
260 the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 15K20936, from Program
261 for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers
262 Grant Number G2801 and from the Leading Initiative for Excellent Young Researchers from the Ministry
263 of Education, Culture, Sport, Science & Technology of Japan. GC acknowledges support from NSF grant
264 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program, and
265 UK Biotechnology and Biological Sciences Research Council grant [BB/M008894/1].

266

267 **Corresponding author:** Eunha Shim. Email: alicia@ssu.ac.kr, Address: 369 Sangdo-ro, Department of
268 Mathematics, Soongsil University, Korea 06978. Tel: +82 (10) 2383-5309. Fax:+82 (2) 824-4383.


269

270 **Figure 1.**




271

272 **Figure 2.**



273

274 **Figure 3.**



275

276 **Table 1.** Summary results of time-delay adjusted case fatality ratio of COVID-19 in the 3 areas in Korea,
 277 2020 (As of March 21st, 2020)

Area	Latest estimate	Range of median estimates during the study period	Crude CFR
Daegu	1.3% (95% CrI [§] : 1.0-1.6%)	1.2-15.4%	1.2% (95% CI [¶] : 0.9-1.4%) 73/6344
Gyeongsanbuk-do	2.4% (95% CrI: 1.6-3.4%)	2.0-81.9%	2.0% (95% CI: 1.2-2.9%) 24/1243
Other regions	0.7% (95% CrI: 0.3-1.4%)	0.6-3.7%	0.4% (95% CI: 0.1-1.0%) 5/1212
Korea (national)	1.4% (95% CrI: 1.2-1.7%)	1.3-17.0%	1.2% (95% CI: 0.9-1.4%) 102/8799

278 [§]CrI: 95% credibility intervals (CrI), [¶]95% CI: 95% confidence interval

279 **Table 2.** Distribution of the cases by sex and age groups, as of Mar 20, 2020 [5]

		Confirmed cases	Deaths # (%)	Fatality rate (%)
		# (%)		
Total		8,652 (100.00)	94 (100.00)	1.09
Sex	Male	3,300 (38.49)	51 (54.26)	1.53
	Female	5,322 (61.51)	43 (45.74)	0.81
Age Group	80 and above	329 (3.80)	33 (35.11)	10.03
	70-79	568 (6.56)	35 (37.23)	6.16
	60-69	1,099 (12.70)	17 (18.09)	1.55
	50-59	1,656 (19.14)	7 (7.45)	0.42
	40-49	1,193 (13.79)	1 (1.06)	0.08
	30-39	893 (10.32)	1 (1.06)	0.11
	20-29	2,365 (27.33)	0 (0.00)	-
	10-19	452 (5.22)	0 (0.00)	-
	0-9	97 (1.12)	0 (0.00)	-

280

281 **References**

- 282 1. WHO. Coronavirus disease (COVID-2019) situation reports.
- 283 2. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19.
- 284 3. Yoo J-H. The fight against the 2019-nCoV outbreak: an arduous march has just begun. *Journal of*
285 *Korean Medical Science* **2019**; 35.
- 286 4. Shim E, Tariq A, Choi W, Lee Y, Gerardo C. Transmission potential and severity of COVID-19 in
287 South Korea. *International Journal of Infectious Diseases* **2020**.
- 288 5. KCDC. The Updates of COVID-19 in Republic of Korea. In: Korea CfDCaP, ed, **2020**.
- 289 6. Association CPM. An update on the epidemiological characteristics of novel coronavirus pneumonia
290 (COVID-19). *Chin J Epidemiol* **2020**; 41:139-44.
- 291 7. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of Novel
292 Coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-
293 driven analysis. *International Journal of Infectious Diseases* **2020**; 93:201-4.
- 294 8. Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early phylogenetic estimate of the effective
295 reproduction number of SARS-CoV-2. *Journal of medical virology* **2020**.
- 296 9. Zhou T, Liu Q, Yang Z, et al. Preliminary prediction of the basic reproduction number of the Wuhan
297 novel coronavirus 2019-nCoV. *Journal of Evidence-Based Medicine* **2020**.
- 298 10. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-
299 infected pneumonia. *New England Journal of Medicine* **2020**.
- 300 11. Mizumoto K, Kagaya K, Chowell G. Early epidemiological assessment of the transmission potential
301 and virulence of 2019 Novel Coronavirus in Wuhan City: China, 2019-2020. medRxiv
302 **2020**:2020.02.12.20022434.
- 303 12. Read JM, Bridgen JR, Cummings DA, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early
304 estimation of epidemiological parameters and epidemic predictions. medRxiv **2020**.
- 305 13. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international
306 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**.

- 307 14. Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing
308 Contacts. *Osong Public Health Res Perspect* **2020**; 11:60-3.
- 309 15. Kwon KT, Ko JH, Shin H, Sung M, Kim JY. Drive-Through Screening Center for COVID-19: a Safe
310 and Efficient Screening System against Massive Community Outbreak. *Journal of Korean medical*
311 *science* **2020**; 35:e123.
- 312 16. Mizumoto K, Chowell G. Estimating Risk for Death from 2019 Novel Coronavirus Disease, China,
313 January-February 2020. *Emerging infectious diseases* **2020**; 26.
- 314 17. Kim JY. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of
315 Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-
316 19 Pneumonia Monitored by Quantitative RT-PCR. *J Korean Med Sci* **2020**; 35:e88.
- 317 18. Mizumoto K, Chowell G. Estimating Risk for Death from 2019 Novel Coronavirus Disease, China,
318 January-February 2020. *Emerging infectious diseases* **2020**; 26.
- 319 19. Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JA. Early epidemiological assessment of the
320 virulence of emerging infectious diseases: a case study of an influenza pandemic. *PLoS One* **2009**;
321 4:e6852.
- 322 20. Tsuzuki S, Lee H, Miura F, et al. Dynamics of the pneumonic plague epidemic in Madagascar,
323 August to October 2017. *Eurosurveillance* **2017**; 22.
- 324 21. Gamerman D, Lopes HF. Markov chain Monte Carlo: stochastic simulation for Bayesian inference.
325 CRC Press, **2006**.
- 326 22. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. *Statistical*
327 *science* **1992**; 7:457-72.
- 328 23. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission
329 dynamics in Wuhan, China. *Nature Medicine* **2020**:1-5.
- 330 24. Yoo J, Chung M, Kim J, et al. Report on the Epidemiological Features of Coronavirus Disease 2019
331 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020.

- 332 25. Lau EH, Hsiung CA, Cowling BJ, et al. A comparative epidemiologic analysis of SARS in Hong
333 Kong, Beijing and Taiwan. *BMC infectious diseases* **2010**; 10:50.
- 334 26. Lessler J, Salje H, Van Kerkhove MD, et al. Estimating the severity and subclinical burden of Middle
335 East respiratory syndrome coronavirus infection in the Kingdom of Saudi Arabia. *American journal of*
336 *epidemiology* **2016**; 183:657-63.
- 337 27. Wong JY, Wu P, Nishiura H, et al. Infection fatality risk of the pandemic A (H1N1) 2009 virus in
338 Hong Kong. *American journal of epidemiology* **2013**; 177:834-40.
- 339 28. Kwok KO, Riley S, Perera RA, et al. Relative incidence and individual-level severity of seasonal
340 influenza A H3N2 compared with 2009 pandemic H1N1. *BMC infectious diseases* **2017**; 17:337.
- 341 29. Yang S, Cao P, Du P, et al. Early estimation of the case fatality rate of COVID-19 in mainland China:
342 a data-driven analysis. *Annals of Translational Medicine* **2020**; 8.
- 343 30. Garske T, Legrand J, Donnelly CA, et al. Assessing the severity of the novel influenza A/H1N1
344 pandemic. *Bmj* **2009**; 339:b2840.
- 345 31. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of
346 severe acute respiratory syndrome in Hong Kong. *The Lancet* **2003**; 361:1761-6.
- 347 32. Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the
348 healthcare setting: a comparative study. *BMC medicine* **2015**; 13:210.
- 349 33. Abdirizak F, Lewis R, Chowell G. Evaluating the potential impact of targeted vaccination strategies
350 against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory
351 syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting. *Theoretical Biology and Medical*
352 *Modelling* **2019**; 16:16.
- 353 34. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic
354 contact in Germany. *New England Journal of Medicine* **2020**.
- 355 35. Liu Y-C, Liao C-H, Chang C-F, Chou C-C, Lin Y-R. A locally transmitted case of SARS-CoV-2
356 infection in Taiwan. *New England Journal of Medicine* **2020**; 382:1070-2.

- 357 36. Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel
358 Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. The
359 Journal of Infectious Diseases **2020**.
- 360 37. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of
361 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama,
362 Japan, 2020. Euro surveillance : bulletin europeen sur les maladies transmissibles = European
363 communicable disease bulletin **2020**; 25.
- 364 38. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19
365 screened among close contacts in Nanjing, China. Science China Life Sciences **2020**:1-6.
- 366